DOCUMENT
CheemaCho_ASTRIS_Supp_Table2.docx (18.48 kB)
DOCUMENT
CheemaCho_ASTRIS_Supp_Table3.docx (15.95 kB)
DOCUMENT
CheemaCho_ASTRIS_Supp_Table4.docx (21.3 kB)
DOCUMENT
CheemaCho_ASTRIS_Supp_Table1.docx (16.34 kB)
DOCUMENT
CheemaCho_ASTRIS_Supp_Table5.docx (23.04 kB)
1/0
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data - supplementary material
dataset
posted on 2023-07-26, 16:10 authored by Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de MarinisSupplemental Table 1. Participating countries and patient enrollment (full analysis set)
Supplemental Table 2. Prior anticancer therapy and prior/relevant medical conditions (full analysis set).
Supplemental Table 3. Protocol deviations (full analysis set).
Supplemental Table 4. Concomitant medications* (full analysis set).
Supplemental Table 5. Baseline patient demographics, characteristics, and EGFR mutation data according to EGFR mutation status combination subgroup.
